Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

manilatimes.net · 2026-10-12

- Trial did not meet the primary endpoint of annualized rate of FVC decline -

TickrTrends take: Syndax's positive topline results from the MAXPIRe Phase 2 trial of axatilimab represent a potential pipeline advancement for INCY, which acquired Syndax in 2021, and could support revenue diversification in its immunology portfolio. Given TickrTrends' undervalued assessment of INCY, investors focused on valuation may want to monitor whether this clinical progress translates into updated guidance or analyst estimates that could close any valuation gap. The idiopathic pulmonary fibrosis market represents a substantial opportunity, so successful phase progression could have meaningful implications for INCY's long-term commercial prospects and near-term market sentiment.

Read the full story at manilatimes.net →